Research at Boston Children's Hospital

The research enterprise at Boston Children’s Hospital, comprising more than 3,000 researchers, is the world’s largest at a pediatric center. Our work is fueled by a deep understanding of disease coupled with world-class discovery platforms, including genetics and genomics, gene editing, bioinformatics, proteomics, bioengineering, image analysis, multiple animal models, biobanks and disease-specific stem cell lines. We have special expertise in rare disease discovery and see large, highly diverse patient populations.

michael rogers and danielle peterse

Find a Researcher

More than 3,000 researchers & scientific staff

Find a Researcher
find a Boston Children

Research Labs

1 million square feet of research space — and growing

Find a Center or Lab
explore Boston Children

Explore Research Topics

$388 million in total research funding FY2018 — #1 NIH funding for pediatric research

Find a Topic

Going into science: Women scientists at Boston Children's offer advice to girls

We gathered women scientists from across Boston Children’s Hospital and asked them to advise girls wanting to enter the field. Hear what they had to say, and go in depth here for more wise words and a taste of what they’re investigating.

Boston Children's Hospital Innovation

BCH Innovation News @BCH_Innovation 9/21/2020 7:00:00 PM
Ultra-high-resolution x-ray #microscopy imaging reveals the brain’s #connectome – great collaboration between…
BCH Innovation News @BCH_Innovation 9/21/2020 3:00:01 PM
The CAMEO tool: Capturing the complex nature of pediatric #nursing:
BCH Innovation News @BCH_Innovation 9/21/2020 12:00:01 PM
Multiple #ATRinhibitors are in clinical development. New work suggests they could target a novel vulnerability in B…
BCH Innovation News @BCH_Innovation 9/20/2020 7:00:00 PM
CAMEO is a powerful tool to help measure cost, quality, and resource allocation on the #nursing floors:
BCH Innovation News @BCH_Innovation 9/20/2020 4:00:01 PM
New research finds bacteria could be a leading cause of diabetes, Alzheimer’s and strokes: via @newscientist
BCH Innovation News @BCH_Innovation 9/20/2020 2:00:07 PM
Inhibition of ATR is a promising therapy for the 10-15% of #nonsmallcell lung cancers in patients with SMARCA4/BRG1…
Building on our extraordinary leadership in pediatric science at Boston Children’s, we translate our findings — and those of others — to fundamentally change how disease is treated and cured.

David A. Williams, MD
Senior Vice President and Chief Scientific Officer